Have a personal or library account? Click to login
Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy Cover

Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy

Radiology and Oncology
Volume 52 (2018): Issue 2 (June 2018)
By:
Open Access
|Sep 2017

Figures & Tables

Figure 1

Taneichi et al. score for spinal bone metastases of the (A) thoracic and (B) lumbar spine.
Taneichi et al. score for spinal bone metastases of the (A) thoracic and (B) lumbar spine.

Figure 2

Bone mineral density measurement in Hounsfield units by manual region of interest setting (A) before radiotherapy and (B) after radiotherapy within the spinal bone metastases.
Bone mineral density measurement in Hounsfield units by manual region of interest setting (A) before radiotherapy and (B) after radiotherapy within the spinal bone metastases.

Figure 3

Overall survival - survival of all patients with urothelial cancer and spinal bone metastases from first diagnosis of urothelial cancer until death.
Overall survival - survival of all patients with urothelial cancer and spinal bone metastases from first diagnosis of urothelial cancer until death.

Figure 4

Bone survival - survival of all patients with urothelial cancer and spinal bone metastases from first diagnosis of spinal bone metastases until death.
Bone survival - survival of all patients with urothelial cancer and spinal bone metastases from first diagnosis of spinal bone metastases until death.

Figure 5

Radiotherapy survival - survival of all patients with urothelial cancer and spinal bone metastases from start of palliative radiotherapy until death.
Radiotherapy survival - survival of all patients with urothelial cancer and spinal bone metastases from start of palliative radiotherapy until death.

Patients’ characteristics of all patients with urothelial cancer and spinal bone metastases

Patients’ characteristics
Age
 Median70 years
 Range35-82 years
n%
Gender
 Female821.0%
 Male3079.0%
Karnofsky performance status
 40-60%1231.6%
 70%1744.7%
 80%923.7%
Histology
 Urothelial carcinoma38100%
Localization of metastases
 Thoracic1847.4%
 Lumbar2052.6%
Number of metastases
 Single1539.5%
 Multiple2360.5%
Distant extra-osseous metastases
 Overall923.7%
 Lungs615.8%
 Liver513.2%
 Brain25.3%
Surgical corset
 Yes615.8%
 No3284.2%
Treatment indications
 Instability718.4%
 Neurological symptoms12.6%
 Pain3079.0%
Radiotherapy schedule
 10 x 3 Gy2463.2%
 14 x 2.5 Gy37.9%
 20 x 2 Gy1128.9%
Systemic therapy
 Chemotherapy1436.8%
 Bisphosphonates410.5%
DOI: https://doi.org/10.1515/raon-2017-0038 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 189 - 194
Submitted on: Jun 9, 2017
Accepted on: Aug 14, 2017
Published on: Sep 14, 2017
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
bone density,
bone metastases,
stability,
survival,
urothelial cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2017 Robert Foerster, Katharina Hees, Thomas Bruckner, Tilman Bostel, Ingmar Schlampp, Tanja Sprave, Nils H. Nicolay, Juergen Debus, Harald Rief, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 52 (2018): Issue 2 (June 2018)Next article